Filing Details
- Accession Number:
- 0001144204-11-056641
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2011-10-05 21:56:41
- Reporting Period:
- 2011-09-27
- Filing Date:
- 2011-10-05
- Accepted Time:
- 2011-10-05 21:56:41
- Original Submission Date:
- 2011-09-28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1176309 | Oramed Pharmaceuticals Inc. | ORMP.OB | Pharmaceutical Preparations (2834) | 980376008 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1298522 | Zeev Bronfeld | 6 Uri Street Tel Aviv L3 64954 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2011-09-27 | 350,000 | $0.28 | 5,808,517 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 781,250 | Indirect | Via DNA Biomedical Solutions Ltd. |
Footnotes
- D.N.A Biomedical Solutions Ltd. ("DNA") owns 781,250 shares of common stock of the Issuer ("Common Stock") and warrants exercisable for 273,438 shares of Common Stock. The Reporting Person holds 22.13% of DNA's outstanding share capital. The Reporting Person and Mr. Meni Mor are parties to a Voting Agreement relating to their shares of DNA, representing, in the aggregate, approximately 44.36% of DNA's outstanding share capital. As a result of the Voting Agreement, the Reporting Person may be deemed a beneficial owner of, and to share the power to vote and dispose, the Issuer securities held by DNA. The Reporting Person disclaims beneficial ownership of any of the Issuer securities held by DNA. The Form 4 is being amended to correct the percentages of DNA outstanding share capital owed by the Reporting Person and Mr. Mor referenced in this footnote.
Billionaire Hedge Funds
